Table 7. In vitro susceptibilities associated with the 9 NNRTI drug resistance mutation patterns.
| Overall Pattern* | Specific Pattern* | %Exact† | %Included† | EFV§ | ETR§ | RPV§ |
|---|---|---|---|---|---|---|
| E138A | E138A | 6.15% | 8.82% | 1.314 | 2.16 | 1.85 |
| E138K | E138K | 0.30% | 0.77% | 1.33 | 2.23 | 2.33 |
| E138GQ | E138G | 0.60% | 1.44% | 1.33 | 1.82 | 1.51 |
| E138Q | 0.09% | 1.16% | 1.23 | - | 2.91 | |
| A98G | A98G | 1.63% | 7.68% | 0.716 | 0.54 | - |
| V179D | V179D | 3.62% | 6.59% | 3.45 | 1.25 | 2.81 |
| K101E | K101E | 0.58% | 7.98% | 2.112 | 1.87 | 1.87 |
| Y181C | Y181C | 3.47% | 22.08% | 1.681 | 5.527 | 2.212 |
| L100I, K103N | L100I, K103N | 2.58% | 4.26% | 20059 | 6.825 | 147 |
| K101E, G190A | K101E, G190A | 1.00% | 4.27% | 839 | 3.43 | 3.12 |
*Mutation patterns are defined as those matching the listed mutations and not containing additional mutations at positions 100, 101, 103, 106, 181, 188, 190, and 230.
†Exact: % of sequences exactly matching the mutation pattern; Included: % of sequences matching or including the mutation pattern.
§Median fold reduced susceptibility as determined by the PhenoSense assay (Monogram Biosciences, South San Francisco). Sequences with electrophoretic mixtures were excluded. “-”indicates that no phenotype results were available for a particular mutation pattern / NNRTI combination. Fold reductions in susceptibility ≥2.5 for RPV and ≥3 for EFV and ETR are in bold. Fold reductions in susceptibility ≥10 are also underlined [5, 11].